论文部分内容阅读
目的:观察瑞格列奈与格列齐特治疗老年2型糖尿病(T2DM)的疗效与安全性。方法:225例年龄>60岁的T2DM患者,随机分为瑞格列奈组(n=112)与格列齐特组(n=113),瑞格列奈组给予瑞格列奈0.5~2 mg,po,tid,格列齐特组给予格列齐特缓释片30~120 mg,po,qd,疗程12周。观察两组患者治疗前后的空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbAlc)、总胆固醇(TC)、三酰甘油(TG)变化情况及不良反应发生情况,比较两组疗效。结果:治疗后,两组患者的FPG、2 h PG、HbAlc、TC均较治疗前显著降低(P<0.05或0.01),且瑞格列奈组患者2h-PG下降更显著(P<0.05),瑞格列奈组与格列齐特组总有效率(91.8%vs 86.2%)、低血糖发生率(4.5%vs 8.2%)及不良反应发生率(6.4%vs 10.1%)差异均无统计学意义(P>0.05)。结论:格列齐特缓释片与瑞格列奈治疗老年T2DM疗效显著,安全性较好。
Objective: To observe the efficacy and safety of repaglinide and gliclazide in the treatment of senile type 2 diabetes mellitus (T2DM). Methods: Totally 225 T2DM patients> 60 years old were randomly divided into repaglinide group (n = 112) and gliclazide group (n = 113), while repaglinide group mg, po, tid, Gliclazide group given Gliclazide extended release tablets 30 ~ 120 mg, po, qd, treatment for 12 weeks. The changes of fasting plasma glucose (FPG), postprandial 2h PG, HbAlc, total cholesterol (TC) and triglyceride (TG) and the incidence of adverse reactions in both groups were observed before and after treatment. Compare the two groups curative effect. Results: After treatment, FPG, 2 h PG, HbAlc, TC in both groups were significantly lower than those before treatment (P <0.05 or 0.01), and 2h-PG decreased more significantly in repaglinide group (P <0.05) , The total effective rate (91.8% vs 86.2%), the incidence of hypoglycemia (4.5% vs 8.2%) and the incidence of adverse reactions (6.4% vs 10.1%) in the repaglinide and gliclazide groups were not statistically different Significance (P> 0.05). Conclusion: Gliclazide sustained-release tablets and repaglinide are effective in treating elderly patients with T2DM.